Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Pharmaceuticals
- Disease
- Therapeutic
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 209572
License Grant
The Company will grant Chinese Licensee an exclusive commercialization license in the territory of the Peoples Republic of China, Macau and Hong Kong, or the Territory, related to the Company’s oral insulin capsule, ORMD-0801. Pursuant to the license agreement, Licensee shall conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Company’s technology and ORMD-0801 capsule.
License Property
Licensor is a clinical-stage biopharmaceutical company developing clinical candidates for the treatment of diabetes by way of oral insulin
ORMD-0801 is anticipated for use as a complementary agent to insulin injections in the treatment of T1DM. Type I diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is an autoimmune disease where the immune system attacks and destroys pancreatic ß cells.
PATENTS
Methods and Compositions for Oral Administration of Proteins
o Patent # ZL20098011 (China)
o Grant Date 10-July-2013
o Priority 61/064,779
Methods and Compositions for Oral Administration of Proteins
o Application # 200680041231.00 (China)
o Filing Date 4-May-2008
o Priority 60/713,716
Protease Inhibitor-Containing Compositions, Compositions Comprising Same, And Methods For Producing And Using Same
o Application # 201380018355.7 (China)
o Filing Date 31-Jan-2013
Oramed “Know How†related to ORMD-0801 consists of
–
Manufacturing/Formulation know-how (“Cookbookâ€)
–
Know-how and capabilities for in vitro/animal testing
–
Analytical capabilities and methods
Field of Use
“Field†means the use of the Product for the treatment of diabetes.
IPSCIO Record ID: 45588
License Grant
The Company will grant Chinese Licensee an exclusive commercialization license related to the Company’s oral insulin capsule, ORMD-0801. Pursuant to the license agreement, Licensee shall conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Company’s technology and ORMD-0801 capsule.
License Property
Licensor is a clinical-stage biopharmaceutical company developing clinical candidates for the treatment of diabetes by way of oral insulin
ORMD-0801 is anticipated for use as a complementary agent to insulin injections in the treatment of T1DM. Type I diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is an autoimmune disease where the immune system attacks and destroys pancreatic ß cells.
Field of Use
“Field†means the use of the Product for the treatment of diabetes.
IPSCIO Record ID: 4140
License Grant
Israeli Licensor shall assign to Israeli Licensee all its right, title and interest in and to the Patent.
License Property
Patent means the patent application in PCT which Oramed filed under international publication number WO 2010/020978A1 entitled Methods and Compositions for Oral Administration of Proteins.
The assigned technology differs from Oramed’s main delivery technology that is used for oral insulin and is subject to a different patent application. Patent involves a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials.
Field of Use
Licensed Field means Diabetes and Influenza.
IPSCIO Record ID: 27724
License Grant
The Licensor will grant a commercialization License related to oral insulin and sales of the related products.
License Property
The Licensor has developed an oral insulin capsule.
Field of Use
The Licensee's businesses are focused on distribution, logistics, sales, R&D and manufacturing of healthcare related products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
